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Preface 
I have been studying antibiotics for the last 35 years, and whenever I 
report a new antibiotic, I receive many letters requesting a sample. 
Even more requests came to my office when I reported a new inhibitor 
of a protease. At present, I receive several letters each week requesting 
leupeptin, pepstatin, phosphoramidon, etc., which indicated that many 
biochemists and biologists are involved in the study of proteases. 
In the last 20 years, in the study of molecular biology great pro-
gress has been made, especially in the structure, function, and bio-
synthesis of DNA, RNA, and protein; and at the present, the study of 
proteases is increasing its importance. Moreover, proteases appear to 
be involved in all kinds of biological phenomena and disease processes. 
I t is said that the number of researchers involved in protease studies is 
now increasing. 
I t seems that, in general, corresponding to each protease, there 
exists an inhibitor. I t is certain that the study of proteases and their 
inhibitors is absolutely necessary for an understanding of biological 
functions and disease processes. 
At present, the structures of these proteins are rapidly de-
termined, and their structures can be displayed on a computer screen, 
being generated from data-base center. Even at this time, low mole-
vi 
cular weight inhibitors are contributing to the identification of pro-
teases and their functions. Therefore, I think it was very fortunate that 
this book included not only the study of endogenous protease inhibitors 
but also of low molecular weight inhibitors. Also I am pleased that 
possible applications of these inhibitors for the treatment of diseases 
are discussed in this book. I should like to thank all contributors to this 
book, and I trust it will surely stimulate us to continue the search for 
new types of enzyme inhibitors. 
July 1983 
Hamao Umezawa 
Editorial Note 
During the past decade the importance of proteolytic processes in the 
regulation of intracellular protein metabolism and the post-translational 
processing of precursor proteins and peptide hormones has been re-
cognized. Various pathological phenomena caused by disorders of these 
proteolytic processes have also been described. Because of this, increas-
ing attention is being given to the rapid development of biochemical 
bases and applications of proteinase inhibitors. 
Proteinase inhibitors can be classified into those which are synthe-
tic and those occurring naturally, the latter obtained from microbial, 
plant, animal and other sources. From a biological aspect, these pro-
teinase inhibitors can be separated into endogenous and exogenous. 
Synthetic and microbial proteinase inhibitors serve as exogenous in-
hibitors not only for the basic biochemistry and biology of proteolysis 
but also for various pathological phenomena and clinical application 
toward certain diseases. Proteinase inhibitors of animal origins play an 
important role in regulation of the self-defense mechanism, blood co-
agulation, intracellular protein catabolism and processing of precursor 
proteins. These inhibitors or their active fragments, i f obtained, may 
find medical application in the future. 
This monograph is a compilation of a substantial portion of the 
vii 
viii 
recent knowledge gained in the medical and biological aspects of pro-
teinase inhibitors. I t is comprised of three sections. The biochemical 
and chemical bases of a number of microbial, plant and synthetic 
proteinase inhibitors are described in the first section. Their basic and 
clinical applications are also discussed. The second section includes 
topics on endogenous proteinase inhibitors from mammalian tissues 
and plasma. The role of these inhibitors in the regulation of proteinase 
activities and physiological functions is described. In the third section 
the biological and pathological significance of intracellular proteinases 
is detailed, and the role of these proteinases in intracellular protein 
degradation, defense mechanism and processing of precursor proteins 
is discussed. Thus the publication offers information on the most recent 
advances in this particular area of science in the fields of biochemistry, 
biology, and medicine. 
On behalf of editors, I wish to cordially thank the authors for 
their cooperation and submission of manuscripts, and I also acknowl-
edge Dr. P.C. Heinrich (Universität Freiburg) and Dr. E. Kominami 
(Tokushima University) for their assistance in the editing, 
July 1983 
Nobuhiko Katunuma 
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Proteinases and Their Inhibitors in Inflammation: 
Basic Concepts and Clinical Implication 
M . JOCHUM,* 1 K . - H . DUSWALD,* 2 S. NEUMANN,*3 
J . W I T T E , * 2 Η . F R I T Z , * 1 a n d U . SEEMÜLLER* 1 
Department of Clinical Chemistry and Biochemistry, University of Munich*1 
Surgical Clinic, University of Munich*'- and Department of Biochemical Research, 
E. Merck*3 
T H E R O L E OF LYSOSOMAL ENZYMES IN INFLAMMATION 
During the inflammatory response various systemic or local tissue cells 
are activated thereby releasing internal, mostly lysosomal enzymes. 
They trigger the activation of the clotting, fibrinolysis and complement 
cascades, the disruption of cell membranes and tissue structure, and 
the release of toxic peptides (Fig. 1). 
Phagocytes, especially the granulocytes and monocytes or macro-
phages, but also fibroblasts, endothelial cells, and mast cells are known 
to be very rich in such internal or lysosomal enzymes. So far, only the 
properties and pathobiochemical effects of enzymes of the azurophilic 
and specific lysosomes of polymorphonuclear granulocytes (neutro-
phils) have been investigated in more detail. Such enzymes, for example 
the neutrophil elastase and cathepsin G as well as the acidic cathepsins 
are preformed and stored in the lysosomes in fully active form (7, 11). 
In this way, they can respond immediately to perform their biological 
*i>*2 D-8000 München 2, F R G . 
* 3 D-6100 Darmstadt 1, F R G . 
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ο Proteases 
° Hydrolases 
° Myeloperoxidase 
H 2 0 2 
Endotoxins 
(endogenous and exogenous) 
Antigen-antibody complexes 
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Toxic peptides: blood pressure j , edema,heart toxicclotting inh. 
Degradation/inactivation: membranes, connective tissue, plasma factors 
Activ. of system-specific proteases: thrombin,plasmin,Cl esterase,kallikrein 
Fig. 1. Liberation and effects of lysosomal factors. For details see text. 
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Specific activation 
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Unspecific degradation 
ο Clotting — f ATHlTff^PI Ί 
° FirbrinolysisfFDP •) f> λ 2 Ρ Ι j <r2M 
° Comp!ement(C3aJ) —-^JoCl INA1 <*iAC 
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|Elimination of enzyme-inhibitor complexes by RES| 
I 1 
Fig. 2. Consumption of plasma factors during inflammation. 
A T I I I , antithrombin I I I ; a 2 PI, a2-plasmin inhibitor; C I I N A , C I inactivator; a x PI , a r 
proteinase inhibitor (formerly a rantitrypsin); a 2 M , a2-macroglobulin; a x A C , a r antichymo-
trypsin; ftCI, ft-collagenase inhibitor; F D P , fibrin(-ogen) degradation products; C3a, 
complement factor. For details see text. 
function, namely, the degradation of extracellular and intracellular 
material after phagocytosis. 
Outside the phagocytes, proteolytic action of the lysosomal en­
zymes is normally prevented or balanced by proteinase inhibitors pre­
sent in plasma, interstitial fluid and body secretions. Non-lysosomal 
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proteinases like, for example, thrombokinases and plasminogen acti-
vators are faced only with a very low inhibitory potential in body 
fluids. They are, therefore, privileged candidates for the activation of 
clotting and fibrinolysis i f released into the circulation after increased 
production due to an inflammatory stimulus. 
Lysosomal enzymes liberated during severe inflammation like sep-
ticemia or septic shock can enhance, together with thrombokinases and 
plasminogen activators, the inflammatory response via two major routes 
characterized by either substrate-specific or substrate-unspecific proteo-
lysis (Fig. 2 ) . 
The system-specific proteinases, thrombokinases and plasminogen 
activators, trigger the activation of the clotting, fibrinolysis and com-
plement cascades (summarized as 'blood systems') by substrate-specific 
proteolysis of proenzymes and cofactors. The activated enzymes are 
subsequently inhibited by their natural inhibitors; the enzyme-inhibitor 
complexes thus formed are rapidly eliminated from the circulation by 
the reticuloendothelial system (RES). Hence, in a series of steps based 
on highly specific interactions not only the proteinases respectively their 
zymogens are consumed but also their natural antagonists, the system-
specific inhibitors. Until recently, the given sequence of reactions was 
assumed to be exclusively responsible for the development of dissemi-
nated intravascular coagulation (DIC). 
Results obtained very recently indicate that an additional reaction 
path may contribute considerably to the consumption of plasma factors 
during severe inflammations. This implies inactivation of plasma factors 
by substrate-unspecific proteolysis due to liberated lysosomal protein-
ases. Egbring and coworkers observed in animals a significant decrease 
in several clotting factors after infusion of endotoxin or human neu-
trophil elastase (4). Similar results were obtained by Ohlsson and 
coworkers (7, 2) in canine endotoxemia. Moreover, in patients suffering 
from sepsis or septic shock a striking consumption of blood system 
factors, immunoglobulins and proteinase inhibitors has been found by 
the teams of Egbring (5), Aasen (5), Gallimore (<5), and Witte (14). 
N E U T R O P H I L E L A S T A S E A N D P L A S M A F A C T O R S I N S E P S I S 
In the following study neutrophil elastase was chosen as a marker 
88 Μ. J O C H U M E T A L . 
enzyme in order to demonstrate the release of lysosomal enzymes 
during the development of septicemia. 
1. Assay of Liberated Elastase 
Due to the presence of an excess of the endogenous inhibitors ax-
proteinase inhibitor (<*iPI) and a2-macroglobulin (<*2M), direct measure­
ment of the neutrophil-derived proteinase activities in plasma or other 
body fluids is not feasible. However, increased levels of the elastase-
<*ΧΡΙ (E-tfiPI) complex would be already a clear indication for elastase 
liberation. Quantitative estimation of the plasma levels of the Ε-α^ΡΙ 
complex was carried out with a highly sensitive enzyme-linked immu­
noassay (12). Briefly, the Ε-α^ΡΙ complex of the plasma sample was 
bound to surface-fixed antibodies directed against neutrophil elastase. 
After washing, a second alkaline phosphatase-labelled antibody directed 
against «αΡΙ was fixed to the complex. Under suitable conditions, the 
activity of fixed alkaline phosphatase towards /?-nitrophenylphosphate 
is proportional to the concentration of the E-c^PI complex in the 
sample. 
In a first approach, we were interested to see whether a relationship 
exists between the plasma levels of Ε-αχΡΙ and the severity of posto­
perative infections. To achieve this purpose, besides other factors the 
levels of factor XIII (Faktor ΧΙΙΙ-Schnelltest, Behringwerke A G Mar­
burg) and antithrombin III (AT III) (S-2238, Deutsche Kabi Munich) 
were continuously monitored because both clotting factors are known 
to be easily degraded by neutrophil elastase in vitro (9). 
2. Patients 
In the clinical trial, patients subjected to major abdominal surgery were 
included if the operation time exceeded 120 min. Diagnosis of septi­
cemia in the postoperative course was confirmed by prospectively 
established septic criteria: 
Defined infection site and pos. bact. culture 
Body temperature>38.5°C 
Leukocytosis with> 15,000 cells/mm3 or 
Leukocytopenia with<5,000 cells/mm3 
Platelets< 100,000/mm3 or drop>30 % 
(Positive blood culture) 
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In the prospective study more than 120 patients were included. Thirty 
of them fulfilled the defined septic criteria during the postoperative 
course. Of these patients, fourteen survived the infection (group B) 
whereas sixteen died as a direct result of septicemia (group C). Eleven 
patients being without infection after abdominal surgery served as 
controls (group A). 
3. E-axPI Levels 
With the enzyme-linked immunoassay elastase levels between 60 and 
110ng/ml were found in 153 healthy individuals. In patients without 
preoperative infection (groups A and B), the operative trauma was 
followed by an increase of the Έ-aJ*! level up to 3-fold of the normal 
value. Patients suffering from preoperative infections (6 out of 16 in 
group C) showed already clearly elevated preoperative E-aJ*! levels. 
Immediately after surgery a slight decrease was observed, probably due 
to elimination of the infection focus. Before onset of sepsis, the Ε-α χΡΙ 
concentrations of group Β and C showed a moderate elevation but no 
significant changes compared to the postoperative levels. However, at 
the beginning of septicemia a highly significant increase of the Ε-α^ΡΙ 
1,000 -
υ 500 > 
σ 
ε 
100 i 
Before Op. After Op. Before sepsis Onset 
of sepsis 
Course of 
sepsis 
R t 
Fig. 3. Plasma levels of E-c^PI in patients subjected to major abdominal surgery. 
Υ///Ά (A) patients (/? = 11) without postoperative infection. Γ^Π (Β) patients (n= 14) surviving 
postoperative septicemia. 1 i (C) patients (« = 16) dying as a result of septicemia. The 
Ε-αχΡΙ levels are given as mean values ( ± S . E . M . ) for the day before operation, the day 
after operation as well as for the postoperative phase before sepsis, at onset of sepsis and 
during septicemia. Last determinations were done on day of discharge (D) for group A , 
on day of recovery (R) for group B, and before death (t) for group C . 
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levels could be detected: up to 6-fold in group Β and up to 10-fold in 
group C. Peak levels were found above 2,500 ng/ml in both groups. 
The E-a xPI levels of septic patients who recovered showed a clear 
tendency towards normal values. In patients with persisting septicemia, 
high levels of E-α^ΡΙ were measured until death (Fig. 3). 
4. AT III Activity 
In non-infected patients the activity of AT I I I , the most important 
inhibitor of the clotting system, was in the normal range during the 
whole observation period. In infected patients, however, the A T I I I 
activity was found already below the clinically critical concentration 
of about 75% of the standard mean value before onset of septicemia. 
This low value normalized in all patients overcoming the infection, 
whereas a further significant decrease (up to 45% of the norm) was 
found in group C patients with lethal outcome. Probably, the extremely 
low AT I I I activity in the latter patients, having permanently elevated 
E-c^PI levels, may be due to a significant degree to degradation by 
lysosomal enzymes and especially by elastase. 
5. Factor XIII Activity and A and S Subunit Levels 
Similar results were obtained for factor X I I I , the fibrin stabilizing co­
agulation factor. In plasma of patients who did not survive septicemia, 
the factor X I I I activity decreased up to 28% of the standard mean 
value. As measured by Immunoelectrophoresis, these patients also had 
very low concentrations of both subunit A, comprising the active en­
zyme, and subunit S, representing the carrier protein (data not shown). 
In contrast, group A patients with an uncomplicated postoperative 
course showed normal or only slightly decreased concentrations of 
subunit S, although subunit A and fibrin stabilizing activities were 
often significantly reduced. 
As demonstrated earlier by Egbring and coworkers (5) and Ike-
matsu and coworkers (5), reduction of both subunits of factor X I I I 
cannot be due to activation of the clotting cascade alone. During clot­
ting, that means by the action of thrombin only subunit A is consumed 
simultaneously with the factor X I I I activity but not subunit S. Elastase, 
however, is able to degrade both subunits to a similar degree. These 
data and the results presented in our clinical trial suggest that in the 
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Fig. 4. Plasma levels of the inhibitory activity of A T I I I (A) compared to the amount of 
the E-o^PI (B) in patients subjected to major abdominal surgery. For details, see legend 
to Fig. 3. 
patients suffering from septicemia, unspecific proteolytic degradation 
by granulocytic elastase and/or other lysosomal proteinases is involved 
to a significant degree in the depletion of factor X I I I . 
6. Conclusion from the Clinical Studies 
The results of the clinical studies show that in inflammatory diseases a 
correlation exists between the release of a lysosomal enzyme marker, the 
neutrophil elastase, and the clinical situation of the patient, respectively, 
the consumption of selected plasma factors. We take this as a clear 
indication that liberated lysosomal factors and especially neutrophil 
proteinases contribute significantly to the inflammatory response of the 
organism by substrate-unspecific degradation of plasma and other 
factors. Early application of suitable and potent exogenous proteinase 
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ng/ml 
1,000 
500 
100 
ifl 
Before After Before Onset Course 0 R t 
Op. O p . sepsis of sepsis of sepsis 
Fig. 5. Plasma levels of the fibrin stabilizing activity of factor X I I I ( F X I I I ) (A) compared 
to the amount of the Ε-α χ ΡΙ (Β) in patients subjected to major abdominal surgery. For 
details, see legend to Fig. 3. 
inhibitors should prevent or at least diminish, therefore, such destruc­
tive proteolytic processes. 
I N H I B I T O R T H E R A P Y I N E X P E R I M E N T A L E N D O T O X E M I A 
To confirm this assumption, we established an endotoxemia model in 
dogs by intravenous infusion of Escherichia coli endotoxin for 2 hr. 
Thereby, a significant decrease was observed in the plasma levels of the 
clotting factors A T I I I , prothrombin, and factor X I I I , of the fibrinolysis 
factors plasminogen and tf2-antiplasmin, and of the complement factor 
C3. The levels were followed up over an experimental period of 14 hr 
and their alterations checked for statistical significance (70) (Fig. 6). 
Simultaneous intravenous administration of a relatively specific 
inhibitor of neutrophil elastase and cathepsin G, the Bowman-Birk 
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0 - I , , r - , J Γ — ' r -τ- , 
0 2 6 10 14 (hr) 0 2 6 10 14 (hr) 
Fig. 6. Changes in the plasma levels of various plasma factors during the acute phase 
of experimental endotoxemia in dogs (n = 6 for each group) without or with inhibitor 
treatment. 
Applied inhibitor dosages: 10-25 trypsin inhibiting units (Bowman-Birk inhibitor) per kg 
body weight over the observation period of 14 hr. Data are given as mean values in per­
centage of the individual starting values. Thick line at the abscissa=endotoxin infusion 
period. For further details see text and ref. 10. A : a, controls, b, endotoxin-treated. B : 
inhibitor and endotoxin-treated. · complement C 3 ; -fc factor X I I I ; Δ prothrombin; A 
A T I I I ; • plasminogen; • antiplasmin. 
inhibitor from soybeans, clearly reduced the endotoxin-induced decline 
of the tested plasma factors. The inhibitor (Mr 7,000) was effective in 
dosages ranging from 3-8 mg (i.e., 10-25 trypsin inhibiting units) per 
kg body weight. A reasonable assumption would be, therefore, that the 
exogenous inhibitor was able to prevent or reduce the neutrophil 
proteinase-induced consumption reactions very effectively. 
E G L I N , A P O T E N T I N H I B I T O R O F N E U T R O P H I L P R O T E I N A S E S 
Another promising candidate for an inhibitor therapy in inflammatory 
processes might be eglin, an inhibitor present in the leech Hirudo 
medicinalis. I t is a mini inhibitor protein with a molecular weight of 
8,100 consisting of a single peptide chain with 70 amino acid residues 
(Fig. 7) (13). Eglin inhibits very strongly the neutral granulocytic pro­
teinases elastase and cathepsin G, as well as chymotrypsin and sub-
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1 10 20 
NH 2 -Thr-Glu-Phe~Gly-Ser-Glu-Leu-Lys -Ser-Phe-Pro-Glu-Val-Val-Gly-Lys -Thr-Val-Asn-Gln-
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Ala-Arg-Glu-Tyr- Phe-Thr-Leu-His -Tyr-Pro-Gln-Tyr-Asp-Val-Tyr-Phe-Leu-Pro-Glu-Gly-
50 60 
Ser -Pro -Val-Thr- Leu -Asn-Leu -Arg-Tyr-Asn-Arg-Val-Arg-Val-Phe-Tyr -Asn-Pro- Gly-Thr-
70 
Asn-Val-Val-Asn-His-Val-Pro-His - V a l - G l y - C O O H 
Fig . 7. Primary structure of eglin, an inhibitor of neutrophil elastase and cathepsin G 
from the leech H. medicinalis. 
tilisin. The dissociation constants are in the range of 10" 1 0 M. Eglin 
might be a useful drug in inflammatory processes which are at least 
partially caused by neutral granulocytic proteinases. 
G E N E R A L C O N C L U S I O N S 
In severe inflammatory processes, multiple trauma or shock, various 
cells such as neutrophils, macrophages, endothelial cells, and mast cells 
are stimulated or disintegrated. In this way a high potential of lyso­
somal enzymes is released of which the proteinases are of special path­
ogenetic effectiveness. Recent studies in our laboratory and by others 
indicate strongly that substrate-unspecific proteolysis by lysosomal pro­
teinases and especially by the neutrophil elastase contributes to a sig­
nificant degree to the consumption and/or degradation of extracellular 
substances in such diseases. On the other hand, early administration of 
convenient exogenous inhibitors directed against the lysosomal enzymes 
should have a positive therapeutic effect also in humans. 
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